問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Neurology

更新時間：2023-09-19

賴秋蓮Lai, Chiou-Lian
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴秋蓮

List

14Cases

2018-06-01 - 2023-03-21

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated6Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

黃錦章
Linkou Chang Gung Medical Foundation

Division of Neurology

2021-02-01 - 2027-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-09-15 - 2030-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-05-18 - 2026-08-21

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-06-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-07-01 - 2022-07-30

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

  • Condition/Disease

    Mild Alzheimer's Disease

  • Test Drug

    Crenezumab

Participate Sites
7Sites

Terminated6Sites

黃錦章
Linkou Chang Gung Medical Foundation

Division of Neurology

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

2015-12-01 - 2021-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer′s Disease

  • Condition/Disease

    Alzheimer′s disease

  • Test Drug

    Aducanumab

Participate Sites
8Sites

Terminated7Sites

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

劉景寬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2009-08-01 - 2012-07-31

Phase III

Effect of Passive Immunization on the Progression of Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated10Sites

2010-05-01 - 2014-07-31

Phase III

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer’s Disease.

  • Condition/Disease

    Alzheimer's disease

  • Test Drug

    Solanezumab

Participate Sites
6Sites

Terminated6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB